Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 10/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368667 | 1.00 | CHRM5 (0.36) | CHRM5ADRA2CDPP4BCHEACHE | |
| SCHEMBL14368654 | 1.00 | CHRM5 (0.36) | CHRM5ADRA2CDPP4BCHEACHE | |
| SCHEMBL14369045 | 0.88 | DPP4 (0.38) | CHRM5ADRA2CDPP4ACHECCR3 | |
| SCHEMBL14368895 | 0.85 | DPP4 (0.46) | DPP4BCHE | |
| SCHEMBL14368921 | 0.85 | DPP4 (0.46) | DPP4BCHE | |
| SCHEMBL14368837 | 0.84 | NPSR1 (0.35) | CHRM5ADRA2CACHECCR3 | |
| SCHEMBL14394457 | 0.84 | NPSR1 (0.35) | CHRM5ADRA2CACHECCR3 | |
| SCHEMBL14368840 | 0.84 | CCR3 (0.32) | CHRM5ADRA2CDPP4BCHEACHE | |
| SCHEMBL14368869 | 0.84 | DPP4 (0.42) | CHRM5ADRA2CDPP4BCHE | |
| SCHEMBL14369104 | 0.84 | CCR3 (0.32) | CHRM5ADRA2CDPP4BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | CHRM5 244/4885ADRA2C 53/4885DPP4 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.